History

Exemestane is a genuine, fully approved prescription drug marketed as Aromasin by Pfizer (originally developed by Pharmacia & Upjohn). The FDA approved it in October 1999 (October 21, 1999) for advanced (metastatic) breast cancer in postmenopausal women whose disease progressed after tamoxifen. In October 2005 the indication expanded to adjuvant treatment of postmenopausal women with ER-positive early breast cancer who switch to exemestane after 2–3 years of tamoxifen to complete roughly five years of endocrine therapy. Despite positive prevention-trial data (the MAP.3 study), it is not FDA-approved for breast-cancer prevention, nor for any male, anti-aging, fertility, or bodybuilding use.

Exemestane, sold as Aromasin, is an oral, steroidal third-generation aromatase inhibitor (AI) — a legitimate, well-studied oncology drug. It is important to be precise about what it is: exemestane is not a peptide, not a SERM (selective estrogen receptor modulator like tamoxifen), and not an anabolic steroid. It works by shutting down the enzyme that makes estrogen, which lowers circulating estradiol throughout the body. In breast-cancer medicine it has a strong, repeatedly published evidence base. In bodybuilding circles it is used off-label to blunt the estrogen produced when aromatizable androgens are taken — a practice that is unapproved, unstudied in that population, banned in sport, and capable of real harm. This page is educational and harm-reduction oriented; it contains no dosing, cycles, stacks, or post-cycle protocols, and no sourcing information.

What it is

Exemestane is a steroidal third-generation aromatase inhibitor. Structurally it is a derivative of androstenedione — the natural substrate of the aromatase enzyme. Unlike the non-steroidal AIs anastrozole and letrozole, which bind reversibly, exemestane is an irreversible “suicide” inactivator (a Type I inhibitor): aromatase processes it into an intermediate that covalently binds the enzyme’s active site, permanently inactivating that enzyme molecule.

Aromatase (CYP19) converts androgens to estrogens, so blocking it lowers circulating estradiol. In postmenopausal women and in men, this dramatically suppresses systemic estrogen. Crucially, exemestane does not block estrogen receptors — that is the mechanism of SERMs such as tamoxifen, which are a different drug class.

The claims

Medically, exemestane is used for ER-positive breast cancer (adjuvant and advanced disease) in postmenopausal women, and in some premenopausal protocols only when combined with ovarian suppression. It has also been studied — but not approved — for risk reduction in higher-risk postmenopausal women.

In the PED context (off-label, illicit, and unapproved), anabolic-androgenic steroid (AAS) and prohormone users take AIs like exemestane to suppress the estrogen produced when aromatizable androgens are converted to estradiol. The stated goals are to limit gynecomastia, water retention, and other estrogen-driven side effects, and sometimes to attempt to restore testosterone after a cycle (estrogen suppression raises LH/FSH and, in turn, testosterone). This is unapproved, unmonitored use; the human evidence below comes from oncology populations, not healthy male athletes, so efficacy and safety claims for PED use are largely extrapolated and poorly studied.

What the evidence actually shows

The oncology evidence base is large and robust.

IES (Intergroup Exemestane Study) — 4,724 postmenopausal women with ER-positive or ER-unknown early breast cancer: switching to exemestane after 2–3 years of tamoxifen improved disease-free survival (HR ~0.76; 354 vs 455 DFS events). The overall-survival analysis showed a favorable trend — 222 deaths (exemestane) vs 261 deaths (tamoxifen), unadjusted HR ~0.85 (95% CI 0.71–1.02) — reaching significance (HR 0.83) when ER-negative patients were excluded. The 10-year long-term follow-up (2017) confirmed a modest, non-significant OS benefit (HR ~0.89).
MAP.3 (Goss et al., NEJM 2011) — prevention: in higher-risk postmenopausal women, exemestane reduced the annual incidence of invasive breast cancer (0.19% vs 0.55% with placebo; HR 0.35) — about a 65% relative reduction at a median follow-up of roughly 35 months. This demonstrated prevention efficacy, but exemestane remains unapproved for that use.
Bone effects (IES skeletal substudy, Coleman 2007): exemestane accelerates bone-mineral-density loss versus tamoxifen and is associated with increased fracture risk — a consistent class effect of AIs, since estrogen is bone-protective.
Endometrial: unlike tamoxifen, AIs do not stimulate the endometrium. The IES long-term endometrial data showed exemestane reverses the endometrial thickening associated with continued tamoxifen and is not linked to the endometrial-cancer signal seen with tamoxifen.

On PED use specifically: there are no high-quality trials showing exemestane is safe or effective for estrogen control in healthy male AAS users. The oncology evidence does not validate that practice.

Legal and regulatory status

US — prescription (Rx) drug. Exemestane is legal only with a valid prescription. Selling or distributing it for human bodybuilding use, or as an unapproved “research chemical,” is illegal. It is not a controlled substance — aromatase inhibitors and SERMs are not scheduled.

For legal clarity, it helps to contrast the compounds that come up alongside it:

Mesterolone and fluoxymesterone are anabolic-androgenic steroids — Schedule III controlled substances under the US Controlled Substances Act.
DNP (2,4-dinitrophenol) is NOT approved for human consumption. The FDA removed it from the market for human use in 1938; it has a long documented history of fatal poisonings and is illegally sold as a “fat burner.”
T3 (liothyronine) and insulin are prescription drugs, not controlled substances, but are dangerous when misused (see Safety).

Anti-doping (WADA 2026 Prohibited List). Exemestane is prohibited at all times (in- and out-of-competition) under S4, “Hormone and Metabolic Modulators.”

S4.1 Aromatase inhibitors — exemestane, anastrozole, letrozole, formestane, testolactone, aminoglutethimide.
S4.2 Anti-estrogenic substances — anti-estrogens and SERMs (e.g., tamoxifen, raloxifene, clomifene).
S4.4 Metabolic modulators — includes insulins and insulin-mimetics, plus agents such as AICAR, GW1516, and SR9009/SR9011.

For context: DNP is prohibited under S4.4 as a metabolic modulator (explicitly named on the list). Anabolic steroids (mesterolone, fluoxymesterone, etc.) fall under S1. Thyroid hormone (T3/liothyronine) is not currently on the WADA Prohibited List.

Safety

Estrogen deprivation drives the main harms of exemestane and the AI class.

Bone: accelerated BMD loss, osteoporosis, and increased fracture risk (documented in IES).
Lipids / cardiovascular: unfavorable lipid changes are possible, and the AI class is associated with cardiovascular and lipid concerns. In men whose estrogen is already low, over-suppression worsens lipids and bone.
Other: arthralgia/joint pain (common and dose-limiting), hot flashes, fatigue, mood effects, low libido and sexual dysfunction (especially in men with crashed estradiol), and hepatic enzyme elevations. In men, estradiol is essential for bone, libido, and lipids — “crashing” estrogen with an AI is genuinely harmful, not benign.

Why PED self-experimentation around exemestane is dangerous comes down in large part to the compounds users combine with it:

DNP — the most lethal item here. It uncouples mitochondrial oxidative phosphorylation, dissipating the proton gradient so cellular energy is lost as heat. This causes uncontrollable hyperthermia (body temperatures reported up to ~44 °C / 111 °F), profuse sweating, tachycardia, and multi-organ failure. There is NO antidote — treatment is only aggressive supportive care and cooling. Numerous deaths are documented, and the effective and lethal doses are dangerously close. DNP kills people; it should never be ingested.
Insulin: non-diabetic misuse for an “anabolic” effect can cause rapid, severe, potentially lethal hypoglycemia, seizures, irreversible brain injury, and death.
SERMs (tamoxifen, clomifene, raloxifene): increased risk of venous thromboembolism (DVT/PE), and, for tamoxifen, endometrial effects.
T3 (liothyronine): misuse causes cardiac arrhythmia, tachycardia, atrial fibrillation, bone loss, and suppression of the endogenous (HPT) thyroid axis that can persist after stopping.

Bottom line

Exemestane is a legitimate, well-studied oncology drug with a clear evidence base in postmenopausal breast cancer — a steroidal, irreversible aromatase inhibitor, not a peptide and not a SERM. Its bodybuilding/PED use to manipulate estrogen is off-label, unapproved, unstudied in that population, banned in sport (WADA S4.1), and carries real risks: bone loss, lipid and cardiovascular harm, and the sexual and mood effects of crashing estrogen, which is genuinely harmful in men. The adjacent compounds users combine it with — especially DNP and insulin — can kill.

Evidence grade: Strong human.

Exemestane (Aromasin)